Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1989-6-16
|
pubmed:abstractText |
Most synthetic peptide vaccines described to date are effective only in combination with proteins and Freund's adjuvant. The work describes a novel completely synthetic virus peptide vaccine, which consists of a synthetic activator of B cells and macrophages, covalently linked to an amphiphilic alpha-helical T-cell epitope. The low-molecular-weight vaccine of 3.4 kDa developed against foot-and-mouth disease virus (FMDV) is composed of a synthetic VP1 (135-154) with a sequence homologous to an FMDV protein and the adjuvant tripalmitoyl-S-glyceryl-cysteinylserylserine (P3CSS). P3CSS is the synthetic analogue of the N-terminal part of the lipoprotein from Gram-negative bacteria. The antigenic determinant VP1 (135-154) is an alpha-helix as shown by circular dichroism. The resulting novel type of vaccine tripalmitoyl-S-glyceryl-cysteinylserylseryl-FMDV-VP1 (135-154) induces a long-lasting high protection against foot-and-mouth disease and serotype-specific virus-neutralizing antibodies in guinea-pigs after a single administration without any additional adjuvant or carrier. In contrast to other simple fatty acid conjugates this new type of vaccine contains a built-in adjuvant with high affinity to both B and T lymphocytes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0264-410X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
29-33
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2470215-Adjuvants, Immunologic,
pubmed-meshheading:2470215-Animals,
pubmed-meshheading:2470215-Antibody Formation,
pubmed-meshheading:2470215-Aphthovirus,
pubmed-meshheading:2470215-B-Lymphocytes,
pubmed-meshheading:2470215-Epitopes,
pubmed-meshheading:2470215-Foot-and-Mouth Disease,
pubmed-meshheading:2470215-Guinea Pigs,
pubmed-meshheading:2470215-Immunization,
pubmed-meshheading:2470215-Immunotherapy,
pubmed-meshheading:2470215-Macrophage Activation,
pubmed-meshheading:2470215-Molecular Weight,
pubmed-meshheading:2470215-Vaccines, Synthetic
|
pubmed:year |
1989
|
pubmed:articleTitle |
Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator.
|
pubmed:affiliation |
Institute of Organic Chemistry, University of Tübingen, FRG.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|